Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 277

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 277
---
 substantially all of the assets of the Company (including, the grant of an exclusive license to all or substantially
all of the intellectual property rights of the Company), in a single transaction or a series of related transactions, the Company and
its shareholders will take such actions as are required to effect a distribution in accordance with Company’s AOA, unless each
of the holders of convertible preferred shares vote collectively against effecting such distribution.

In the event of an IPO, the conversion
price of the preferred shares shall be adjusted to reflect a deemed liquidation distribution to the preferred shares as provided in the
AOA, such that the number of Ordinary Shares issuable upon conversion thereof reflects that number of Ordinary Shares that would have
been distributed with respect the preferred shares in a distribution made according to the AOA at the pre-money valuation of the IPO.

Although the preferred shares are not
redeemable, in the event of certain “Deemed Liquidation Event” that are not solely within the Company’s control (including
merger, acquisition, or sale of all or substantially all of the Company’s assets), the holders of the preferred shares are entitled
to preference amounts paid before distribution to other shareholders (as explained in the previous paragraph) and, hence, effectively
redeeming the preference amount. The preferred shares are classified outside of shareholders’ deficit as a result of these in-substance
contingent redemption rights.

As of December 31, 2024, the Company
did not adjust the carrying values of the preferred shares to the deemed liquidation values of such shares since a liquidation event
was not probable of occurring.

<div align='center'>F-26</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 11:- | SHAREHOLDERS’ DEFICIT |

:

Ordinary Shares confer to holders the
right to receive notice to participate and vote in the general meetings of the Company and the right to receive dividends if declared.
However, certain ordinary shareholders, who received those shares upon their exercise of options pursuant to the Company’s share
option plan, have signed an irrevocable proxy appointing the Chairman of the Company’s board of directors to use the voting rights
of their Ordinary Shares.

:

As of December 31, 2024 and 2023, there
79,290 options outstanding to purchase its Ordinary Shares, at an exercise price of $3.